By Carolyn McCoy, MPH
Senior Policy Manager, Health Reform Implementation, AMCHP
The Association of State and Territorial Health Officials (ASTHO) recently released a state story highlighting the efforts of Louisiana to expand use of 17-alphahydroxyprogesterone (17P). 17P is an injectable form of progesterone that has been proven effective in preventing recurrent preterm birth.
In Louisiana, only 5 percent of women who are eligible to receive 17P do so. By linking vital records with Medicaid and creating a Medicaid pay-for-performance measure, the state plans to raise this rate to 20 percent. The State Story highlights: steps taken, including how public health works with Medicaid, results that include data collection improvements and metrics, and lessons learned that can help other states improve use of 17P.
Among many results of the Louisiana work on this topic, they have seen a quadrupling in home injection of 17P and improved collection of data to help track the progress of this effort.
The State Story can be found here: http://www.astho.org/Maternal-and-Child-Health/Louisiana-Public-Health-and-Medicaid-Team-Up-to-Increase-17P-Access-and-Reduce-Preterm-Birth-Rate/.